Searchable abstracts of presentations at key conferences on calcified tissues

ba0003pp209 | Muscle, physical activity and bone | ECTS2014

Does bone density, bone strength, sarcopenia or dynapenia explain greater risk of fracture in obesity?

Evans Amy , Eastell Richard , Walsh Jennifer

Obesity is associated with greater risk of proximal humerus and ankle fracture, despite greater areal BMD (aBMD). We aimed to investigate whether greater risk of some fractures in obesity was due to skeletal or non-skeletal determinants. 100 individually-matched pairs of normal weight (NW) (18.5–24.9 kg/m2) and obese (OB) (BMI >30 kg/m2) individuals, aged 25–40 and 55–75 years underwent DXA to determine hip and lumbar spine aBMD, whole ...

ba0003pp386 | Other diseases of bone and mineral metabolism | ECTS2014

Bone mineral density and micro-architectural changes in advanced chronic kidney disease

Salam Syazrah , Khwaja Arif , Eastell Richard

Background: Risk of fracture in chronic kidney disease (CKD) population is high and it is associated with increased mortality. CKD affects bone quality through changes in bone turnover, microarchitecture, and mineralization. Secondary hyperparathyroidism has different effects on cortical and trabecular bone but dual-energy X-ray absorptiometry (DXA) is unable to effectively differentiate these bone compartments. High resolution peripheral quantitative computed tomography (HRpQ...

ba0004p133 | (1) | ICCBH2015

Fibrodysplasia ossificans progressiva: disabling but now treatable

Keen Richard , Jacobs Benjamin , Mughal M Zulf

Background: Fibrodysplasia ossificans progressiva (FOP) is a rare condition characterised by congenital malformation of the great toes and progressive heterotopic endochondral ossification. The disease progresses with episodic flare-ups, resulting in disabling cumulative immobility. The discovery of the ACVR1 gene as the cause of FOP has allowed identification of therapeutic targets. Palovarotene, a retinoic acid receptor gamma agonist, is in phase 2 clinical trials.<...

ba0005p403 | Osteoporosis: treatment | ECTS2016

Biochemical monitoring of teriparatide efficacy in a real world setting

Pigott Thomas , Eastell Richard , Peel Nicola

Teriparatide is an anabolic agent given to reduce fracture risk in osteoporosis; it increases BMD and bone turnover. For monitoring treatment efficacy, serum PINP shows the greatest increase and low variability; it has been proposed as a marker of individual treatment response. We aimed to evaluate the utility of PINP to monitor teriparatide treatment in clinical practice.We performed a retrospective evaluation of 91 patients treated with teriparatide si...

ba0001pp209 | Cell biology: osteoblasts and bone formation | ECTS2013

Bone marrow stromal cells of female BAG-1 heterozygous mice exhibit reduced osteogenic potential

Greenhough Joanna , Townsend Paul , Oreffo Richard , Tare Rahul

The co-chaperone protein, Bcl-2-associated athanogene 1 (BAG-1) is expressed ubiquitously in bone including cells of the osteoblast-lineage and, plays an important role in cell proliferation, apoptosis and differentiation by regulating signalling and transcription. The study aims to elucidate the function of BAG-1 in osteoblast development by examining differences in osteogenic differentiation of bone marrow stromal cells (BMSCs) from Bag-1+/−</sup...

ba0003pp294 | Osteoporosis: treatment | ECTS2014

Targeting the sealing zone, a novel strategy to prevent bone degradation while maintaining bone formation: in vivo proof of concept in three models of pathological bone loss

Vives Virginie , Cress Gaelle , Richard Chrtistian , Blangy Anne

Molecules secreted by the osteoclast or ‘clastokynes’ are essential to stimulate bone formation by osteoblasts. Treatments with bisphosphates and Denosumab target osteoclast survival and differentiation. This suppresses bone turnover and is suspected to increase the risk of atypical fractures in the long term. A solution to overcome this is to develop strategies that target selectively the activity of osteoclasts without affecting their survival or differentiation. S...

ba0005p454 | Other diseases of bone and mineral metabolism | ECTS2016

Bone mineral density and vascular calcification in obesity

Bouquegneau Antoine , Walsh Jennifer , Evans Amy , Paggiosi Margaret , Eastell Richard

Background: The presence of vascular calcification (VC) is a predictive factor for the development of cardiovascular diseases, especially in the obese population. VC has also been inversely associated with bone mineral density (BMD) but the results have been inconsistent. The main aim of this study was to evaluate the associations between VC, obesity and volumetric BMD (vBMD).Methods: We studied 148 healthy men and women, aged 55–75 years, divided i...

ba0006p011 | (1) | ICCBH2017

Neonatal hypocalcemia – transient neonatal pseudohypoparathyroidism

Kutilek Stepan , Vracovska Martina , Pikner Richard , Fejfarkova Zlatka

Background: Neonatal hypocalcemia is defined as S-Ca <2 mmol/l in fullterm newborns and <1.75 mmol/l in preterm newborns. Neonatal hypocalcemia is either early onset (<3 days of age) or late onset (>3 days of age). Newborns with hypocalcemia are often asymptomatic, but mays present with hypotonia, apnea, poor feeding, jitteriness, seizures, cardiac failure. Signs of hypocalcemia rarely occur unless S-Ca drops below 1.75 mmol/l.Case presen...

ba0006p117 | (1) | ICCBH2017

Uptake of influenza vaccine in UK patients with fibrodysplasia ossificans progressiva

Gak Nataliya , Vinton Jacqueline , Jacobs Benjamin , Keen Richard

Fibrodysplasia ossificans progressiva (FOP; OMIM #135100) begins in childhood and leads to irreversible restriction of movement, functional impairment, and shortened life-span. Individuals with FOP develop progressive limitations in chest expansion, resulting in restrictive lung disease. Current management guidelines published in 2011 (1) highlight that Influenza may be a causative factor for FOP flare-ups, and can also cause potentially deadly cardiopulmonary complications, e...